-+ 0.00%
-+ 0.00%
-+ 0.00%

Cullinan Therapeutics wins FDA orphan drug designation for CLN-049 in relapsed AML

PUBT·05/19/2026 11:02:50
Listen to the news
Cullinan Therapeutics wins FDA orphan drug designation for CLN-049 in relapsed AML
  • Cullinan Therapeutics received FDA Orphan Drug Designation for CLN-049 in relapsed or refractory acute myeloid leukemia.
  • CLN-049 is an investigational FLT3xCD3 T-cell engager in a Phase 1 program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605190700PRIMZONEFULLFEED9722297) on May 19, 2026, and is solely responsible for the information contained therein.